Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3748819 | 1.00 | ESR2 (0.50) | ESR2KDM4EPKMCYP2C9CYP2C19 | |
| SCHEMBL12385989 | 1.00 | ESR2 (0.50) | ESR2KDM4EPKMCYP2C9CYP2C19 | |
| Hydrochloric Acid SCHEMBL28232795 | 0.97 | ESR2 (0.48) | ESR2KDM4EPKMCYP2C9CYP2C19 | |
| SCHEMBL13924884 | 0.85 | — | — | |
| SCHEMBL17706160 | 0.79 | KDM4E (0.34) | ESR2KDM4EPKMCYP2C9CYP2C19 | |
| SCHEMBL3012888 | 0.79 | KDM4E (0.34) | ESR2KDM4EPKMCYP2C9CYP2C19 | |
| SCHEMBL17835264 | 0.79 | KDM4E (0.34) | ESR2KDM4EPKMCYP2C9CYP2C19 | |
| SCHEMBL13523771 | 0.77 | KDM4E (0.33) | ESR2KDM4EPKMCYP2C9CYP2C19 | |
| SCHEMBL25568146 | 0.77 | KDM4E (0.37) | ESR2KDM4EPKMCYP2C9CYP2C19 | |
| SCHEMBL898237 | 0.76 | KDM4E (0.44) | KDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461328-B2 | Tricyclic heterocyclic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | CCNY, CCNA1, CCNA2 | ESR2 790/4885KDM4E 2333/4885PKM 1313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.